Abstract: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.

Abstract: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.

Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Abstract: Disclosed are compounds, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses.

Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Abstract: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.

Abstract: Disclosed are compounds and compositions of Formula (I) and their uses for treating Flaviviridae family virus infections.

Abstract: Disclosed are compounds and compositions of Formula (A) and their uses for treating Flaviviridae family virus infections.

Abstract: Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R2, m, R, V, W, T, Z, R1, Y, and p are disclosed herein.

Abstract: Disclosed are compounds having Formula (I) and the compositions and methods relating to these compounds, for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R2, m, R, V, W, T, Z, R1, Y, and p are disclosed herein.

Abstract: Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus.

Abstract: A method for administering a loan includes the steps of debiting a first account in the name of a borrower with one or more payments of capital, calculating an interest amount based on an outstanding balance on the first account and debiting at least a portion of the interest amount to a second account, in a name other than the name of the borrower, such that no interest is debited to the first account. An electronic system facilitating the use of the above method for administering a loan.

Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus.

Abstract: Disclosed are compounds having formula I and related compositions and methods thereof. The compounds are useful for treating viral infections caused by the Flaviviridae family of viruses.

Abstract: Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

Abstract: Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

Abstract: The present invention relates to a compound of the following formula: or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating ?L?2 adhesion mediated conditions in a mammal.

Abstract: A wireless device operating under the IEEE 802.11 specifications passively scans for a wireless access point coupled to a network backbone, wherein the scanning is performed using a default set of channels. The wireless device will then determine if the access point operates under an IEEE 802.11d specification, thus providing a country code to the wireless device. The wireless device will then utilize the country code to determine if the wireless device is legally authorized to communicate with the selected access point with wireless signal channels in addition to the default set of channels. The wireless device can then communicate with a selected access point utilizing any of the default set of channels and the wireless signal channels in addition to the default set of channels.

Abstract: A method that utilizes both software and combination software and hardware mechanisms to comply with the FCC requirement for an U-NII antenna to be an integral part of the device, while providing CRUable dual mode wireless cards and wireless-ready U-NII devices. Enhancements are made to the system BIOS and Device Driver, and two new software-implemented utilities are provided to create authentication schemes that verify and authenticates the CRUable dual mode U-NII radio and antenna combination as being an FCC approved unique coupling during operation of the system. The system boots with only ISM transmission capability and is allowed to complete a U-NII transmission request only with an approved U-NII radio-antenna combination.